Results 81 to 90 of about 2,609,461 (289)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

open access: yesMolecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis   +3 more
wiley   +1 more source

Graphic Medicine [PDF]

open access: yes
Attendees will get an overview of graphic medicine, hear about the history of graphic medicine at the Charles M. Baugh Biomedical Library, learn about the artistic process of creating comics, and hear about uses for graphic medicine in educational and ...
Coleman, Leesha   +2 more
core  

Critical Design for Overdose Response: Graphic Medicine as a Tool to Address Stigma

open access: yesSocieties
This paper examines the role of graphic medicine as a critical design tool that should be used in harm reduction messaging, focusing on its capacity to address barriers to opioid overdose response.
Gillian Harvey   +2 more
doaj   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

open access: yesMolecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder   +10 more
wiley   +1 more source

04-0044_SecureCore Graphic

open access: yes, 2004
Matthew Rose worked at the Naval Postgraduate School as a graphic designer from February 2002-November 2011. His work for NPS included logos, brochures, business packs, movies/presentations, posters, the CyberSiege video game and many other projects ...
Rose, Matthew
core  

Boston University School of Medicine catalog [PDF]

open access: yes, 1897
Course catalog and informational material for the Boston University School of ...
Boston University School of Medicine
core   +2 more sources

MITF maintains genome stability in nonmelanocyte lineages

open access: yesMolecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir   +13 more
wiley   +1 more source

The Ethical Zombie: A Review of The Walking Med: Zombies and The Medical Image

open access: yesThe Comics Grid: Journal of Comics Scholarship, 2017
This review offers insight into the collection The Walking Med: Zombies and The Medical Image edited by Lorenzo Servitje and Sherryl Vint (Penn State Press, 2016) by putting it into the context of George A Romero’s recent death (16 July 2017), and the ...
Andrew Godfrey
doaj   +2 more sources

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy